AxeroVision: Developing Breakthrough Treatments for Dry Eye Disease

/

Eyecelerator@AAO 2021
Subset 2: Novel Topical Rx

Carlsbad, CALIF. (November 11, 2021) – AxeroVision, a privately held clinical stage biotech company, shared data on its pipeline products during Eyecelerator at the 2021 American Academy of Ophthalmology meeting in New Orleans. Houman Hemmati, MD, PhD, head of clinical development, presented data for AXR-270 (cream). Phase 3 clinical trials for AXR-270 will be initiating soon.

Highlights of the AXR-270 phase 2 study overview included:

  • AXR-270 is a novel, proprietary, once-daily selective glucocorticoid receptor agonist cream investigated in patients with signs and symptoms of moderate to severe dry eye disease associated with meibomian gland dysfunction

  • Improvement from baseline in all signs and symptoms over 3 weeks in AXR-270 0.2% cream arm of study (meaningful to patients)

  • Statistically significant improvement in eye discomfort and tear break-up time with AXR-270 0.2% cream vs vehicle

Additional details can be found in the AXR-270 Phase 2 Results press release.